Lilly Alzheimer's drug does not slow memory loss: Study

Lilly shares tumble after its Alzheimer drug study did not meet its goals, reports CNBC's Meg Tirrell. Obviously we are disappointed but we remain committed to Alzheimer's disease, says John Lechleiter, Eli Lilly CEO. And David Ricks, Eli Lilly incoming CEO, weighs in on the company's future growth prospects.
Wed, Nov 23 20167:27 AM EST